Business

Feliza Mirasol is the science editor for 

Articles

With the agreement, Andelyin Biosciences will add MyoAAV plasmids developed by Broad Institute of MIT and Harvard to its AAV Curator Platform.

Andelyn Biosciences and Broad Institute of MIT Enter into License Agreement to include MyoAAV Plasmids in AAV Platform

Mike Hennessy Jr. is the President and CEO of 

Will Sanofi’s plan to recruit the younger generation through its participation in the upcoming 2024 Olympic and Paralympic Games, being held in Paris, pay off?

Igniting Pharma’s Potential?

This acquisition gives AbbVie clinical-stage assets from Cerevel’s pipeline that complement AbbVie's emerging neuroscience pipeline and branded products for treating psychiatric disorders, migraine, and Parkinson's disease.

AbbVie Strengthens Neurological Pipeline with $8.7 Billion Acquisition of Cerevel Therapeutics

With the Series A funding, the new biotech company will advance the development of enhanced biologics for treating solid tumors and inflammatory and immunology diseases.

Third Arc Bio to Advance Biologic Drug Development Programs on $165 Million Funding 

With this acquisition, AstraZeneca gets a Phase III therapeutic peptide candidate that adds to the company's rare disease pipeline.

AstraZeneca Completes Amolyt Pharma Acquisition and Boosts Rare Disease Pipeline

Merck gains a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration through its acquisition of EyeBio.

Merck Gains Late-Stage Eye Disease Drug Candidate with EyeBio Acquisition

The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.

Lantheus Acquires Meilleur Technologies, PET Imaging Agent

Thermo Fisher will add Olink to its Life Sciences Solutions business.

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.

Pfizer and Evotec Partner for Drug Discovery

The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services. 

Business News